Parexel announced that Synairgen has signed a collaboration agreement with Parexel Biotech for a Phase 3 trial of Synairgen’s SNG001 nebulized interferon-beta-1a for the treatment of COVID-19. In July 2020, Synairgen announced positive results from a Phase 2 trial of SNG001 in COVID-19 patients hospitalized in the UK. The Phase 3 SG018 trial is expected to enroll 900 patients in about 20 countries.
Parexel Biotech Senior VP and Global Head of Operations Graciela Racaro commented, “There is a distinct sense of urgency, paired with a clear need for safety, in the race to find a treatment for the most debilitating and deadly consequences of COVID-19. Working with Synairgen, we are able to share our global reach, deep therapeutic expertise and innovative approaches to support a pivotal study of their novel, inhaled therapy.”
Synairgen CEO Richard Marsden said, “In the past, we’ve always run our own clinical trials, working with hospitals and research centers. In the case of the SG018 trial, however, there is a clear need to find a global partner to ensure a smooth, fast, and successful trial. We look forward to working with Parexel Biotech as we progress this potential breakthrough therapy for COVID-19 patients.”
Read the Parexel press release.
